Abstract TP171: Higher Social Vulnerability Index is Associated with Declination of Stroke Clinical Trial Enrollment

Background: Neurological clinical trials often underrepresent the diversity of those affected.Patients with higher social vulnerability index (SVI), driven by poverty, limited transportation, and crowded housing, may face barriers potentially restricting participation. Additionally,trials seldomly capture social determinants of health (SDOH) or their impact on trial recruitment thereby limiting generalizability of results. Objective: This study seeks to examine how social vulnerability influences trial enrollment and demographic differences amongst eligible patients.We aim to identify potential patterns in declination to enroll in stroke clinical trials to inform strategies for inclusive participation,thereby improving trial access95%CI 0.01;0.62,(p=0.015)) with enrolled patients demonstrating a statistically significant lower SVI median 0.565 (95%CI,0.5406,0.5730) versus non-enrolled with median SVI 0.692 (95%CI,0.5646,0.7686), with significant group differences (W=6203,p=0.004). Older age also reduced enrollment odds (OR=0.93;95%CI 0.9;0.96,(p<0.001)) with median age 67 amongst enrollees (95%CI,65,69) versus 78.6 amongst non-enrollees (95%CI,74.5,81.5) with statistically significant group differences (W=11137,p<0.0001). While not statistically significant, race and sex were underrepresented when compared to national and local inpatient ischemic stroke demographics amongst Black and female patients. Conclusion: Older age and higher SVI negatively impacted enrollment of eligible patients in this small longitudinal stroke recovery clinical trial,highlighting underrecruitment of disadvantaged populations. SDOH, while rarely captured in trials, pose barriers to participation thus prospectively incorporating them into future studies can facilitate targeted recruitment and retention thus critically promoting equitable participation and enhancing trial accuracy and generalizability.